Medexus Pharmaceuticals (TSE:MDP) Trading 3% Higher – What’s Next?

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) rose 3% during trading on Thursday . The company traded as high as C$2.74 and last traded at C$2.72. Approximately 11,567 shares were traded during trading, a decline of 88% from the average daily volume of 93,972 shares. The stock had previously closed at C$2.64.

Analyst Upgrades and Downgrades

MDP has been the topic of several recent research reports. Stifel Canada lowered Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Ventum Financial increased their target price on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a report on Thursday, January 30th. Finally, Stifel Nicolaus lowered shares of Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price target for the company from C$6.00 to C$3.45 in a report on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of C$5.49.

Medexus Pharmaceuticals Price Performance

The company has a market capitalization of C$60.90 million, a price-to-earnings ratio of 13.01 and a beta of 1.96. The stock has a 50-day moving average price of C$2.53 and a 200-day moving average price of C$2.90.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.